A Phase 4 interventional study of exemestane in Breast Neoplasms, sponsored by Pfizer. Completed at 63 sites in Belgium. Open to female participants. Per ClinicalTrials.gov, last updated 2008-09-29.
Sponsored by Pfizer · Phase 4, Interventional, and Treatment
The purpose of this study was to give access to postmenopausal women with estrogen sensitive primary breast cancer to exemestane for the adjuvant treatment of breast cancer after the use of tamoxifen and to collect all serious adverse events.
12,544 studies on the registry are indexed under Breast Neoplasms; 2,892 are open to participants now.
This study's enrollment of 1,549 is above the median of 72 across 9,303 interventional studies indexed under Breast Neoplasms.
Browse Breast Neoplasms studies →Pfizer is the lead sponsor of 3,244 studies on the registry; 139 are open to participants now.
Of its 582 completed or terminated interventional studies of FDA-regulated products, 381 (65%) have results posted.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
Drug: exemestane
Exemestane 25 mg oral tablet once daily for a maximum of 3 years
Assess for serious adverse events
Time frame: Months 3, 6, 12, 18, 24, and 30; Follow-up visit 28 days posttreatment
Safety Surveillance Program
Time frame: Duration of trial
This study is completed, as verified in Sep 2008. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Pfizer